Aequus Pharmaceuticals AQSZF Stock
Aequus Pharmaceuticals Price Chart
Aequus Pharmaceuticals AQSZF Financial and Trading Overview
| Aequus Pharmaceuticals stock price | 0.0030 USD |
| Previous Close | 0.03 USD |
| Open | 0.03 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.03 - 0.03 USD |
| 52 Week Range | 0.0013 - 0.1 USD |
| Volume | 100 USD |
| Avg. Volume | 7.75K USD |
| Market Cap | 3.48M USD |
| Beta (5Y Monthly) | 0.624338 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
AQSZF Valuation Measures
| Enterprise Value | 6.27M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.9768095 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 5.356 |
| Enterprise Value/EBITDA | -2.585 |
Trading Information
Aequus Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.624338 |
| 52-Week Change | -52.42% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.1 USD |
| 52 Week Low | 0.0013 USD |
| 50-Day Moving Average | 0.02 USD |
| 200-Day Moving Average | 0.03 USD |
AQSZF Share Statistics
| Avg. Volume (3 month) | 7.75K USD |
| Avg. Daily Volume (10-Days) | 12.22K USD |
| Shares Outstanding | 132.63M |
| Float | 112.79M |
| Short Ratio | N/A |
| % Held by Insiders | 14.96% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -259.67% |
| Operating Margin (ttm) | -207.82% |
| Gross Margin | 88.64% |
| EBITDA Margin | -207.24% |
Management Effectiveness
| Return on Assets (ttm) | -67.40% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 1.17M USD |
| Revenue Per Share (ttm) | 0.009 USD |
| Quarterly Revenue Growth (yoy) | -69.50% |
| Gross Profit (ttm) | N/A |
| EBITDA | -2424175 USD |
| Net Income Avi to Common (ttm) | -3037481 USD |
| Diluted EPS (ttm) | -0.01 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 44.18K USD |
| Total Cash Per Share (mrq) | 0 USD |
| Total Debt (mrq) | 2.86M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.086 |
| Book Value Per Share (mrq) | -0.016 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -2103769 USD |
| Levered Free Cash Flow (ttm) | -1274203 USD |
Profile of Aequus Pharmaceuticals
| Country | United States |
| State | BC |
| City | Vancouver |
| Address | 200 Granville Street |
| ZIP | V6C 1S4 |
| Phone | N/A |
| Website | https://www.aequuspharma.ca |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 12 |
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Q&A For Aequus Pharmaceuticals Stock
What is a current AQSZF stock price?
Aequus Pharmaceuticals AQSZF stock price today per share is 0.0030 USD.
How to purchase Aequus Pharmaceuticals stock?
You can buy AQSZF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aequus Pharmaceuticals?
The stock symbol or ticker of Aequus Pharmaceuticals is AQSZF.
Which industry does the Aequus Pharmaceuticals company belong to?
The Aequus Pharmaceuticals industry is Drug Manufacturers-Specialty & Generic.
How many shares does Aequus Pharmaceuticals have in circulation?
The max supply of Aequus Pharmaceuticals shares is 159.34M.
What is Aequus Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Aequus Pharmaceuticals PE Ratio is now.
What was Aequus Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Aequus Pharmaceuticals EPS is -0.01 USD over the trailing 12 months.
Which sector does the Aequus Pharmaceuticals company belong to?
The Aequus Pharmaceuticals sector is Healthcare.